Physician profile
Emily Tuthill
NPI 1366519324
$2,728.59
in general payments reported to CMS, 2019-2025
14 companies · $262 in 2025
The $262 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $287 · 2020: $188 · 2021: $327 · 2022: $992 · 2023: $401 · 2024: $272 · 2025: $262.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $935.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $934.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $968.82 | 2019-2025 | Acuvue |
| Coopervision INC. | $342.77 | 2019-2024 | Myday Contact Lens, Biofinity Contact Lens, Clariti Contact Lens |
| Bausch & Lomb Americas INC. | $324.01 | 2022-2025 | Miebo, Infuse, Vyzulta |
| Sun Pharmaceutical Industries INC. | $267.27 | 2019-2025 | Cequa |
| Alcon Vision LLC | $252.51 | 2020-2025 | Total30, Precision7, Precision 1 |
| Oyster Point Pharma, INC. | $208.64 | 2022-2024 | Tyrvaya, Ryzumvi |
| Novartis Pharmaceuticals Corporation | $111.96 | 2021-2023 | |
| Abbvie INC. | $69.70 | 2022-2023 | Lumigan, Vuity, Alphagan P |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $52.94 | 2019-2021 | |
| Genentech USA, INC. | $45.95 | 2019 | |
| Allergan, INC. | $32.18 | 2021 | |
| Eyevance Pharmaceuticals LLC | $18.59 | 2020 | |
| Sight Sciences, INC. | $18.20 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $15.05 | 2025 | Xdemvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Tuthill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.